Press releaseGlobe Newswire
Regeneron Pharmaceuticals
REGN · NASDAQ
$807.48+$25.44 (+3.25%)TodayMarket closed ·
Prev close $782.04
Latest news
- NewsVandana Singh
Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth
- Press releaseGlobe Newswire
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
- Press releaseGlobe Newswire
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
- NewsPiero Cingari
Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average
- NewsVandana Singh
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data
- Press releaseGlobe Newswire
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
- Press releaseGlobe Newswire
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
- NewsVandana Singh
Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion
- Press releaseGlobe Newswire
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
- Press releaseGlobe Newswire
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
- NewsVandana Singh
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
- NewsVandana Singh
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
- Press releasePRNewswire
REGN DEADLINE ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. Investors to Today's September 14, 2026 Lead Plaintiff Deadline in Securities Class Action
- Press releaseBusiness Wire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
- Press releaseBusiness Wire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
- Press releasePRNewswire
REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
- Press releaseGlobe Newswire
REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
- Press releaseGlobe Newswire
REGN SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
- Press releaseGlobe Newswire
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - REGN
- Press releaseBusiness Wire
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
- Press releasePRNewswire
REGN 4-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
- Press releasePRNewswire
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
- Press releasePRNewswire
Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class Action
- Press releasePRNewswire
REGN MONDAY DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
- Press releasePRNewswire
Levi & Korsinsky Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN
- Press releaseGlobe Newswire
REGN 6-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
- Press releaseGlobe Newswire
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - RGRD Law
- Press releasePRNewswire
REGN 1-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
- Press releaseGlobe Newswire
Robbins LLP Urges REGN Investors to Contact the Firm Before the September 14, 2026, Lead Plaintiff Deadline in the Class Action Against Regeneron Pharmaceuticals, Inc.
- Press releaseBusiness Wire
SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
- Press releasePRNewswire
REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit
- Press releasePRNewswire
REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure
- Press releasePRNewswire
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact SueWallSt
- Press releaseGlobe Newswire
Regeneron Reports Second Quarter 2026 Financial and Operating Results
- Press releaseGlobe Newswire
Regeneron Reports First Quarter 2026 Financial and Operating Results
- Press releaseGlobe Newswire
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
- NewsAvi Kapoor
This Lowe's Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday (CORRECTED)
- NewsAvi Kapoor
'No One's Buying Homes Here': Cramer Warns On This Housing Stock
- NewsAvi Kapoor
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
- Press releaseGlobe Newswire
Regeneron Reports Third Quarter 2025 Financial and Operating Results
- NewsAvi Kapoor
Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday
- NewsAvi Kapoor
Cisco, ServiceNow, Truist Financial And A Health Care Stock On CNBC's 'Final Trades'
- News
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.